Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure

European Journal of Clinical Investigation

Volumn 36, Issue 11, 2006, Pages 771-778

  Stoiser, B ^a   Mortl D ^a   Hulsmann M ^a   Berger, R ^a   Struck, J ^b   Morgenthaler, N G ^b   Bergmann, A ^b   Pacher, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BRAHMS AG   (Germany)

Author keywords

Copeptin; Heart failure; Natriuretic peptides; Prognosis; Vasopressin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COPEPTIN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; GLYCOPEPTIDES; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 33749987205     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01724.x     Document Type: Article

References (27)

1. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind randomized trial. Circulation 2003;107:2690-6.
2. Gheorghiade M, Gattis W, O'Connor C, Adams K, Elkayam U, Barbagelata A et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA 2004;291:1963-71.
3. Francis G, Benedict C, Johnstone D, Kirlin P, Nicklas J, Liang C et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9.
4. Rouleau J, Packer M, Moye L, de Champlain J, Bichet D, Klein M et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583-91.
5. Wada K, Fujimori A, Matsukawa U, Aray Y, Sudoh K, Yatsu T et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol 2005;507:145-51.
6. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I et al. Acute hemodynamic effects of conivaptan, a dual V (1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.
7. Morgenthaler N, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-19.
8. Struck J, Morgenthaler N, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26:2500-4.
9. Berger R, Huelsmann M, Strecker K, Bojic A, Moser P, Stanek B et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
10. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.
11. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP et al. For the Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
12. Cleland J, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Cosin-Aguilar J et al. On behalf of the Study Group of diagnosis of the Working Group on heart failure of the European Society of Cardiology. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:422-63.
13. Schrier R, Abraham W. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-87.
14. Yamamoto T, Kimura T, Ota K, Shoji M, Inoue M, Sato K et al. Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion. Am J Physiol 1992;262:856-62.
15. Goldsmith S. Vasopressin as vasopressor. Am J Med 1987;82:1213-19.
16. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998;28:198-205.
17. Ebert T, Cowley A, Shelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest 1986;77:1136-42.
18. Walker B, Childs M, Adam E. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinerg receptors. Am J Physiol 1988;255:261-5.
19. Uretsky B, Verbalis J, Generalovich T, Valdes A, Reddy P. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol 1985;248:396-402.
20. Landry D, Levin H, Gallant E, Ashton R, Seo S, Dálessandro D et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5.
21. Preibisz J, Sealey J, Laragh J, Cody R, Weksler B. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983;5:129-38.
22. Goldsmith S, Franics G, Cowley A, Levine T, Cohn J. Increased plasma arginin vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;6:1385-90.
23. Richards A, Doughty R, Nicholls M, Macmahon M, Ikram H, Sharpe N et al. Neurohumoral prediction of benefit from Carvedilol in ischemic left ventricular dysfunction. Circulation 1999;99:786-92.
24. Nakamura T, Funayama H, Yoshimura A, Tsuruya Y, Saito M, Kawakami M et al. Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. Int J Cardiol 2006;106:191-5.
25. Burrel L, Phillips P, Risvanis J, Chan R, Aldred K, Johnstone C. Long-term effects of nonpeptide vasopressin V2-antagonist OPC-31260 in heart failure in the rat. Am J Physiol 1998;275:176-82.
26. Hirano T, Ymammura Y, Nakamura S, Onogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000;292:288-94.
27. Ven Kerckhoven R, Lankhuizen I, van Veghel R, Saxena P, Shoemaker R. Chronic vasopressin V (1A) but not V (2) receptor antagonism prevents heart failure in chronically infracted rats. Eur J Pharmacol 2002;449:135-41.